Adjuvant Sacituzumab Govitecan & Pembrolizumab vs. SOC tx in patients with TNBC

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

 A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

For More Information:

https://clinicaltrials.gov/study/NCT05633654?term=%20A%20Randomized,%20Open-label,%20Phase%203%20Study%20of%20Adjuvant%20Sacituzumab%20Govitecan%20and%20Pembrolizumab%20Versus%20Treatment%20of%20Physicians%20Choice%20in%20Patients%20with%20Triple%20Negative%20Breast%20Cancer%20Who%20Have%20Residual%20Invasive%20Disease%20After%20Surgery%20and%20Neoadjuvant%20Therapy&rank=1